Antonio Flores

Dr. Antonio Flores


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2025 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
MCMaria Ruano Camps
Maria Ruano Camps
AFAntonio Flores
Antonio Flores
ACAleny Couto
Aleny Couto
IGIrénio Gaspar
Irénio Gaspar
SYSabine Yerly
Sabine Yerly
Edy NacarapaEdy Nacarapa
Edy Nacarapa
Background: Treatment failure continues to play a role in HIV-related morbidity in Mozambique. Antiretroviral therapy (ART) regimen switches are decided empirically, as HIV genotypic resistance testing (HIV-GT) is unavailable in Mozambique’s public health system. Since 2016, Médecins Sans Frontières (MSF) and I-TECH have provided access to HIV-GT at Alto Maé Health Center, Maputo. We describe the cohort of people with virologic failure (VF) that underwent HIV-GT and analyze dolutegravir (DTG) resistance (R) patterns. Methods: This cross-sectional assessment of routine programmatic data between July 2020 and February 2024 was conducted to guide future program enhancements. People living with HIV (PLWH) receiving ART beyond the first line with confirmed VF were included. Mutations were interpreted according to the Stanford HIVdb algorithm. We applied Bayesian bootstrapping for analysis, and the threshold for significance of effects was defined as a probability of 95%. Results: A total of 106 persons underwent HIV-GT following a structured adherence strategy, 62 (58.5%) of whom were on a DTG-based regimen. Fifty-seven of the 62 samples from persons on a DTG-based regimen were sequenced, and 51 (89.5% [95% CrI: 80.7, 96.2]) had confirmed resistance to DTG; the mean DTG-R score was 70.2 (95% CrI: 62.2, 78). Samples with DTG-R had a median of three INSTI mutations (IQR 1–4). Major DTG-associated mutations were found in 46 out of 57 samples: G118R (n = 28), R263K (n = 15), and Q148RK (n = 7). None of the people on the protease inhibitor regimen had an INSTI mutation. Conclusions: In contexts with limited access to resistance testing, the introduction of algorithms to identify PLWH at risk of developing drug resistance is strongly recommended. The proposed algorithm incorporates adherence reinforcement strategies, as recommended in national policies, followed by a short, supervised antiretroviral therapy (ART) support strategy. This approach has shown a high predictive value for identifying PLWH with resistance mutations to dolutegravir (DTG), thereby allowing the continuation of the effective DTG regimen without unnecessary regimen switches.

17 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMaria Ruano Camps
Maria Ruano Camps
AFAntonio Flores
Antonio Flores
ACAleny Couto
Aleny Couto
IGIrénio Gaspar
Irénio Gaspar
SYSabine Yerly
Sabine Yerly
Edy NacarapaEdy Nacarapa
Edy Nacarapa
Background: Treatment failure continues to play a role in HIV-related morbidity in Mozambique. ART regimen switch is decided empirically as HIV genotypic resistance testing (HIV-GT) is unavailable in Mozambique’s public health system. Since 2016, Médecins Sans Frontières (MSF) and I-TECH have provided access to HIV-GT at Alto Maé Health Centre, Maputo. We describe the cohort of people with virologic failure (VF) that underwent HIV-GT and analyze dolutegravir (DTG) resistance (-R) patterns. Methods: This cross-sectional assessment of routine programmatic data between December 2020 and February 2024 was conducted to guide future program enhancements. PLWH receiving ART beyond the first line with confirmed VF were included. Mutations were interpreted according to the Stanford HIVdb algorithm. We applied Bayesian bootstrapping for analysis, and the threshold for significance of effects was defined as probability 95%. Results: Total of 106 persons underwent HIV-GT, 62 (58.5%) of whom were on a DTG-based regimen. Fifty-seven of the 62 samples from persons on a DTG-based regimen were sequenced, and 51 (89.5% [95% CrI: 80.7, 96.2]) had confirmed resistance to DTG; the mean DTG-R score was 70.2 (95% CrI: 62.2, 78). Samples with DTG-R had a median of 3 INSTI mutations (IQR 1-4). Major DTG-associated mutations were found in 46 out of 57 samples G118R (n = 28), R263K (n=15), and Q148RK (n=7). The mean relative DTG-R score (the DTG-R score standardized by total number of INSTI mutations) was 20.6 (95% CrI: 19, 22.2). The relative DTG-R score was positively correlated with the number of major mutations (bootstrapped Pearson’s correlation coefficient, r: 0.61 [95% CrI: 0.42, 0.77; pd: 100%]). None of people on a protease inhibitor regimen had any INSTI mutation. Conclusions: In contexts with limited access to genotyping testing, the introduction of algorithms to identify PLWH at risk of developing drug resistance is strongly recommended. The proposed algorithm incorporates adherence reinforcement strategies, as recommended in national policies, followed by a short, supervised antiretroviral therapy (ART) support strategy. This approach has shown a high predictive capacity for identifying PLWH with resistant mutations to dolutegravir (DTG), thereby allowing the continuation of the effective DTG regimen without unnecessary regimen switches.

23 August 2024 in The Lancet HIV
Verified
Journal Article
Closed access
AFAntonio Flores
Antonio Flores
BCBuai Tut Chol
Buai Tut Chol
JAJane Alphonse
Jane Alphonse
THTess Hewett
Tess Hewett

18 December 2024 in The Lancet Global Health
Verified
Journal Article
Open access
AFAntonio Flores
Antonio Flores
DFDiego R Falci
Diego R Falci